The American Hospital Association (AHA) is calling on the Food and Drug Administration (FDA) to develop evaluation standards and measurements to assess the impacts of medical tools that use artificial intelligence.

On Monday, AHA Senior Vice President for Public Policy Analysis and Development Ashley Thompson responded to a request from the FDA for an evaluation of AI-enabled medical devices.

“AI-enabled medical devices offer tremendous promise for improved patient outcomes and quality of life,” the AHA wrote. “At the same time, they also pose novel challenges — including model bias, hallucinations and model drift — that are not yet fully accounted for in existing medical device frameworks.”

The AHA said it supports AI policy frameworks that “balance flexibility to drive market-base

See Full Page